A new survey by Rochester, NY-based Harris Interactive reveals that public perception of the pharmaceutical, health insurance, managed care and hospital industries continues to decline. The survey, which was conducted by telephone among a nationwide sample of 1,014 adults, measures how many people believe particular industries are doing a good or bad job of serving their customers.
A new survey by Rochester, NY-based Harris Interactive reveals that public perception of the pharmaceutical, health insurance, managed care and hospital industries continues to decline. The survey, which was conducted by telephone among a nationwide sample of 1,014 adults, measures how many people believe particular industries are doing a good or bad job of serving their customers.
In the three years prior to this year's study, public perceptions of much of the healthcare industry fell dramatically. The percentage of those who said the industries do a good job of serving consumers dropped as follows:
•Â Hospitals: from 77% to 67%.
•Â Pharmaceutical or drug companies: from 79% to 59%.
•Â Health insurance companies: from 55% to 39%.
•Â Managed care companies: from 51% to 29%.
In comparison, this year's data show relatively little change. Only the proportion of respondents who indicated that hospitals are doing a good job changed significantly (down from 72% to 67%).
Regarding the health insurance industry, data show that rating declines may be in part due to physicians imparting negative attitudes toward managed care to their patients and friends, patients communicating their bad experiences rather than good ones to others, and consumers absorbing greater costs for insurance and incurring higher out-of-pocket expenses for healthcare services.
"For those working in healthcare or any of the different healthcare industries, the key question is, of course, 'Where do the numbers go from here?'" said Humphrey Taylor, chairman of The Harris Poll, Harris Interactive. "And the answer is, 'We don't know,' or 'It depends.' Quite possibly, these low ratings have bottomed out and will improve. But on the whole, we doubt it. The forces that have damaged public perception of health insurers, managed care and the pharmaceutical companies are still in place and are, we believe, likely to inflict more damage over the next few years." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.